Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study).
Bella JN, Wachtell K, Boman K, Palmieri V, Papademetriou V, Gerdts E, Aalto T, Olsen MH, Olofsson M, Dahlöf B, Roman MJ, Devereux RB. Bella JN, et al. Among authors: boman k. Am J Cardiol. 2002 Feb 1;89(3):337-41. doi: 10.1016/s0002-9149(01)02238-x. Am J Cardiol. 2002. PMID: 11809439 No abstract available.
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
Gerdts E, Papademetriou V, Palmieri V, Boman K, Björnstad H, Wachtell K, Giles TD, Dahlöf B, Devereux RB; Losartan Intervention For End (LIFE) point reduction in hypertension study. Gerdts E, et al. Among authors: boman k. Am J Cardiol. 2002 Feb 15;89(4):399-402. doi: 10.1016/s0002-9149(01)02260-3. Am J Cardiol. 2002. PMID: 11835919
Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Gerdts E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K, Dahlöf B, Devereux RB; Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Gerdts E, et al. Among authors: boman k. Hypertension. 2002 Mar 1;39(3):739-43. doi: 10.1161/hy0302.105683. Hypertension. 2002. PMID: 11897755
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Devereux RB, et al. Among authors: boman k. Circulation. 2004 Sep 14;110(11):1456-62. doi: 10.1161/01.CIR.0000141573.44737.5A. Epub 2004 Aug 23. Circulation. 2004. PMID: 15326072 Clinical Trial.
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
Narayan P, Papademetriou V, Wachtell K, Gerdts E, Boman K, Nieminen MS, de Simone G, Dahlöf B, Fyhrquist F, Hoieggen A, Devereux RB. Narayan P, et al. Among authors: boman k. Hypertension. 2006 May;47(5):868-73. doi: 10.1161/01.HYP.0000215578.40687.6f. Epub 2006 Mar 27. Hypertension. 2006. PMID: 16567586
411 results